STRONG BUY

A large position for him. They bring tech to the healthcare industry, like software. They had a previous business that they grew, then sold to private equity and finished their non-competes, and now they're doing that again with a new product that is starting to produce cash. Margins have risen to 24%, and they target 40%. It's becoming a cash engine that they're using to reinvest in products. They have a ton of cash as they grow 10-15% organically.

DON'T BUY

Never owned this. They carry way too much debt.

BUY

They bring validation software to biopharma, and they do it well. The chart is strong. He's been adding shares. Before, they were losing as they invested in R&D, but now they're becoming profitable. He expects margins to expand quickly in coming years. When they win a client, it takes time to roll out that client. Growth is safe.

BUY

A large holding of his. A UK acquisition will be accretive and will diversify their geography. 2026 revenues are +40 and earnings +70, as it trades at 10-11x. Lots of growth ahead. 

DON'T BUY

Very small, trying to be the Paladin Labs of veterinarian services. They lack the compounding cash flow engine to reinvest. They just bought a Winnipeg company and took on too much debt which limits growth.

BUY

The chart shows a massive spike up, massive drop, and now recovery in the past year.  They likely paid too much for a company in 2022 and were trading at a high PE. He had added shares in 2023-4 after a new CEO started bundling products, focus on margins and integrated companies. Has been doing a good job. He expects them to return to growth this year at 10% organically and 18% EBITDA margins. Looks cheap, half the PE of peers.

DON'T BUY

He sold it after rising 300% for him. Problem now are their capacity constraints. They're growing capacity in Guelph and New Mexico, but you're overpaying on limited growth. He doesn't see the growth, considering their PE.

DON'T BUY

Never owned it. After it went public, it was growing revenue at 80%, but was unprofitable. He can't value a company losing money. But SHOP Is shifting: revenue growth is falling as margins rise. It trades at 103X PE, which is not good considering their growth rate.

WAIT

Is currently reorganizing, spinning off Well Star (like Vitalhub) and that price is too high. WELL may also spin off more businesses. What will the balance sheet look like? He's on the sidelines.

DON'T BUY

He owned it when they were a typical Canadian compounder, reinvesting cash into tuck-ins, but it became lumpy. That's when he sold. They spiked during Covid, because they had a telehealth business, so YOY comps later didn't look good. Also, how does AI impact their large call centre business?

DON'T BUY

It's had some CEOs over the years. Doesn't know if he fully trusts the management style going forward in light of past mistakes. Are better companies in security. See Top Picks.

DON'T BUY

They provide back-end software in hundreds of millions of cars, plus they have a strong cybersecurity business. They aren't growing that quickly. Trading at 30x PE. Still not super cheap.

DON'T BUY

They face the US tariff risk. The PE looks cheap, but look at the balance sheet. Lots of debt. Growth is declining.

DON'T BUY

Not high-growth. Balance sheet isn't clean. And there's political pressure to open up the teleco market. There are safer places.

BUY

Has followed it a long time and should have bought it. They compound their capital extremely well. Management executes. A great business.